drugset / Trial / NCT02137382

A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT02137382

Phase 3 Completed 41 enrolled Abbott
RandomizedCrossoverQuadruple-blindTreatment

Summary

maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis

Timeline

Start
2014-01
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Creon N Unknown 8000 iu/kg
Subject Creon N Unknown 10000 iu/kg
Subject Pancrelipase Protein / enzyme biologic 8000 iu/kg
Subject Pancrelipase Protein / enzyme biologic 10000 iu/kg